"ACOPP"化疗治疗老年和不太适合的患者霍奇金淋巴瘤-A多中心,回顾性研究研究
Matthew R Wilson1, Euan Haynes2, Katrina Parsons1
1Department of Haematology, Beatson West of Scotland Cancer Centre, Glasgow, UK.
British journal of haematology
|June 26, 2023
概括
一种修改后的化疗方案,ACOPP,在老年经典霍奇金淋巴瘤患者中显示出良好的毒性和有前途的疗效. 这种治疗为患有并发病的老年人提供了更安全的选择.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 临床药理学 临床药理学
背景情况:
- 老年人的古典霍奇金淋巴瘤 (cHL) 管理因化学疗法不耐受而复杂.
- 像BEACOPP这样的标准治疗方案 (布莱米辛,埃托波西德,多克索鲁比辛,环胺,温克里斯,普罗卡巴,普雷迪尼索隆) 对于患有并发症的老年患者来说往往过于有毒.
研究的目的:
- 评估改性化疗方案 (ACOPP) 在患有cHL的老年患者的安全性和有效性.
- 评估该修改方案的与治疗相关的死亡率 (TRM) 和长期结果 (无进展生存率 (PFS) 和整体生存率 (OS)).
主要方法:
- 一种经过修改的BEACOPP疗法,称为ACOPP,是通过去除白素和埃托波西德并降低环胺剂量来开发的.
- 从三个中心的首批41名用ACOPP治疗的cHL患者收集了数据.
主要成果:
- ACOPP治疗方案已成功地向患有并发症的老年患者提供.
- 观察到2%的低治疗相关死亡率 (TRM).
- 实现了73% (95% CI: 52-94) 的有前途的2年无进展生存率 (PFS) 和93% (95% CI: 80-100) 的2年整体生存率 (OS).
结论:
- 修改后的ACOPP疗法在老年cHL患者中显示出有利的毒性概况.
- ACOPP显示出有希望的疗效,这表明它是这种脆弱患者群体的可行治疗选择.
相关概念视频
Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...


